Marc Verlasky
Nurse Practitioner · San Diego, CANPI 1053645903
Payments from drug & device makers
Across 159 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$688
- Abbott$614
- Novartis$389
- AstraZeneca$343
- Merck$226
- Daiichi Sankyo Inc.$168
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,436100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 37 | $688 |
| Abbott | 28 | $614 |
| Novartis | 19 | $389 |
| AstraZeneca | 18 | $343 |
| Merck | 10 | $226 |
| Daiichi Sankyo Inc. | 7 | $168 |
| Kestra Medical Technology Services, Inc. | 6 | $167 |
| Alnylam Pharmaceuticals Inc. | 5 | $108 |
| Bridgebio Pharma, Inc. | 5 | $95 |
| Cvrx, Inc. | 1 | $95 |
| Bayer | 5 | $94 |
| Pfizer | 3 | $73 |
| Lilly USA, LLC | 3 | $69 |
| Scpharmaceuticals Inc. | 2 | $62 |
| Boehringer Ingelheim | 2 | $55 |
| Sobi, Inc | 2 | $51 |
| Novo Nordisk | 2 | $46 |
| Lexicon Pharmaceuticals, Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Analog Devices Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $14 |
How this compares
$3,436 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 43 | $41,039 |
| JardianceEmpagliflozin | 24 | $23,391 |
| EliquisApixaban | 21 | $17,037 |
| EntrestoSacubitril/Valsartan | 14 | $15,849 |
| Sirolimus | 23 | $5,364 |
| Mycophenolic AcidMycophenolate Sodium | 15 | $4,350 |
| Tacrolimus | 58 | $4,337 |
| Valganciclovir Hcl | 14 | $3,661 |
| Mycophenolate Mofetil | 32 | $2,435 |
| Potassium Chloride | 32 | $978 |
| Rosuvastatin Calcium | 30 | $662 |
| Hydralazine Hcl | 49 | $615 |
| Bumetanide | 25 | $613 |
| Pantoprazole Sodium | 68 | $599 |
| Losartan Potassium | 43 | $413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $55 | $23,39124 claims |
| PfizerEliquis | $73 | $17,03721 claims |
| NovartisEntresto | $389 | $15,84914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in San Diego
- Angelina CollinsSan Diego$356K
- Madison ShreeveSan Diego$310K
- Arlene OrtegaSan Diego$135K
- Stacey RossSan Diego$43K
- Timothy LazarekSan Diego$37K
- Melanie McGillowaySan Diego$33K
- Jeremy FlowersSan Diego$26K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.